US Patent Issued to Medicenna Therapeutics on Sept. 2 for "Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof" (Canadian Inventor)

ALEXANDRIA, Va., Sept. 3 -- United States Patent no. 12,404,497, issued on Sept. 2, was assigned to Medicenna Therapeutics Inc. (Toronto).

"Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof" was invented by Fahar Merchant (Vancouver, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides an oncolytic virus vector containing a sequence encoding IL-4 receptor targeted cargo protein, including IL-4 muteins and/or IL-13 muteins, the oncolytic virus encoded therefrom, the uses of the oncolytic virus for treating cancer."

The patent was filed on June 3, 2019, under Application No. 15/733,815.

*For further information, including images, charts and table...